Brief: Hoth Therapeutics Says 100% Of Patients Achieved Primary Endpoint In HT-001 Phase 2A Trial
24/06/2025 16:04
June 24 (Reuters) - Hoth Therapeutics Inc HOTH.O: HOTH THERAPEUTICS HT-001 INTERIM RESULTS FIRST-IN-CLASS TOPICAL THERAPY PRESERVES CANCER TREATMENT WHILE RESOLVING DERMATOLOGIC SIDE EFFECTS HOTH THERAPEUTICS INC - 100% OF PATIENTS ACHIEVED PRIMARY ENDPOINT IN PHASE 2A TRIAL HOTH THERAPEUTICS INC - TOPICAL THERAPY WELL TOLERATED WITH NO SERIOUS ADVERSE EVENTS Source text: ID:nPnbrgm3ja Further company coverage: HOTH.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Rocket One
See all newsBrief: Rocket One Signs AI Chip Development Agreement Targeting Ultra-Low-Power Magnetic Computing
Brief: Rocket One Signs Agreement To Advance Nanomagnetic Ai Chip Technology And Device Prototyping
Brief: Rocket One Signs Patent License Agreement With U.S. Air Force For Technology Designed To Capture And Neutralize Hostile Drones
Brief: Rocket One To Buy 100% Ownership Of Tracer Drone Technologies
Brief: Rocket One And Nasa Reach Agreement To Advance Space Ai Technology